Allergan Tazorac partnership
Executive Summary
Allergan seeking Tazorac (tazarotene) development partner for Phase III acne trials, company says Nov. 25. "This decision is based on the size of the market for the acne indication, the potential in other channels outside of dermatology, as well as the cost of this clinical program compared with other significant opportunities in Allergan's portfolio." Allergan submits tazarotene NDA for moderate to severe psoriasis the same day...